Conflicts of interest always present problems (to some degree)

As our friend Howard Wolinsky continues his journalistic exploits into the world of prostate cancer, he has (almost inevitably) come across an issue of “conflicts of interest”, … READ MORE …

The role of the phi test prior to decisions about prostate biopsies

Yesterday morning, a newly published paper was brought to my attention. It reports that use of the Prostate Health Index or phi test in a partially prospective study can and did change urologists’ opinions about whether selected patients really do or don’t need to have a prostate  biopsy. … READ MORE …

Are genomic tests “up to snuff” for routine use in prognosis of prostate cancer risk?

The Intergroupe Coopérateur Francophone de Recherche en Onco-urologie (ICFuro) has just published a review of the available evidence on the clinical validity and utility of six prognostic biomarkers available for the assessment of prostate cancer-related risk. … READ MORE …

Can phi density accurately predict risk for clinically significant prostate cancer?

A new article in BJU International has suggested the possibility that Prostate Health Index density (i.e., a patient’s phi score divided by his prostate volume) may be able to predict the probability of a finding of clinically significant prostate cancer on biopsy. … READ MORE …

The Prostate Health Index (phi test) and the need for biopsy

It will come as no great surprise to regular readers that your Sitemaster has been less than enthusiastic to date about the potential of the Prostate Health Index or phi test as a tool for assessment of risk for prostate cancer. However, new data is starting to give him slightly greater hope regarding the value of this test. … READ MORE …

NICE concludes that PCA3, phi tests not clinically useful

The National Institute for Health and Care Excellence (NICE) has issued draft guidance stating that two approved tests for risk of prostate cancer are not clinically useful in England. … READ MORE …

Can the phi test accurately predict who should go on active surveillance?

In more data reported at ASCO yesterday afternoon, we got the first real look at what appears to be a helpful study designed to evaluate whether the Beckman Coulter Prostate Health Index (or phi) test is really able to identify men who are good candidates for active surveillance. … READ MORE …

Old and newer tests and risks for prostate cancer; can you avoid inappropriate biopsy?

We now have five approved tests that can (at least in theory) help a man — and his doctors — to decide whether he is at sufficient risk for clinically significant prostate cancer that he should go get a biopsy. But how good are they really? … READ MORE …

What’s the best predictor of prostate cancer after a prior negative biopsy?

According to a recent prospective study from a group of Italian investigators, the answer to that question is, “Multiparametric magnetic resonance imaging” (mp-MRI). However, this needs to be confirmed in at least one other large, prospective study. … READ MORE …

“Northwestern Medicine debuts new prostate test …”

We’re a tad flummoxed by a media release from Northwestern Medicine in Chicago stating that it is “the first health care provider in the country to offer a new non-invasive blood test for prostate cancer that is nearly three times more accurate than the current standard prostate-specific antigen (PSA) blood test.” … READ MORE …

Coming soon? — Beckman Coulter’s “Prostate Health Index”

At the annual meeting of the European Association for Urology (which ends today in Barcelona), there was a sponsored symposium entitled, “Prostate Health Index (phi) – A simple blood test significantly improves on PSA in the selection of men for biopsy and is a major advance in prostate cancer risk assessment.” … READ MORE …